Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Baigent C. et al, (2011), Lancet, 377, 2181 - 2192

Authors' reply

Baigent C. et al, (2011), The Lancet, 377, 715 - 716

Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis.

Mafham M. et al, (2011), PLoS One, 6

Ezetimibe/simvastatin (vytorin) in heart and renal protection: The SHARP trial

Alexander W. et al, (2011), P and T, 36

Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study.

Landray MJ. et al, (2010), Am J Kidney Dis, 56, 1082 - 1094

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Cholesterol Treatment Trialists’ (CTT) Collaboration None. et al, (2010), Lancet, 376, 1670 - 1681

Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.

Sharp Collaborative Group None., (2010), Am Heart J, 160, 785 - 794.e10

Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men.

Emberson JR. et al, (2010), J Intern Med, 268, 145 - 154

Antiplatelet therapy: aspirin for asymptomatic atherosclerosis?

Patrono C. and Baigent C., (2010), Nat Rev Cardiol, 7, 306 - 307

Clinical Trials and Meta-Analysis

Emberson JR. and Baigent C., (2010), 26 - 37

Revascularization versus medical therapy for renal-artery stenosis.

ASTRAL Investigators None. et al, (2009), N Engl J Med, 361, 1953 - 1962

Aspirin in the primary prevention of vascular disease - ATT secretariat's reply

Baigent C. et al, (2009), The Lancet, 374

Effect of statins on atrial fibrillation: a collaborative meta-analysis of randomised controlled trials

Rahimi K. et al, (2009), EUROPEAN HEART JOURNAL, 30, 450 - 451

Effect of statins on ventricular arrhythmic events: a collaborative meta-analysis of randomised controlled trials

Rahimi K. et al, (2009), EUROPEAN HEART JOURNAL, 30, 591 - 591

UNDERSTANDING THE USES AND LIMITATIONS OF RCTS

Baigent C., (2009), BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 105, 1 - 2

Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial.

CLOTS Trials Collaboration None. et al, (2009), Lancet, 373, 1958 - 1965

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Antithrombotic Trialists' (ATT) Collaboration None. et al, (2009), Lancet, 373, 1849 - 1860

Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies.

Prospective Studies Collaboration None. et al, (2009), Lancet, 373, 1083 - 1096

Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges.

Patrono C. and Baigent C., (2009), Mol Interv, 9, 31 - 39

Cholesterol and lipids

Baigent C. and Clarke R., (2008), 693 - 704

Load More

«
...
8
9
10
11
12
13
14
...
»

Include forthcoming?